Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of Risankizumab and Adalimumab in Children with Active Juvenile Psoriatic Arthritis

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called risankizumab in children with a condition known as juvenile psoriatic arthritis. Juvenile psoriatic arthritis is a type of arthritis that affects children and is associated with a skin condition called psoriasis, which causes red, scaly patches on the skin. The study will also compare risankizumab to another medication called adalimumab, which is already used to treat this condition. Both medications are given as injections under the skin.

The purpose of the study is to evaluate how well risankizumab works, how safe it is, and how it is processed by the body in children aged 5 to under 18 years who have active juvenile psoriatic arthritis. These children may not have responded well to other treatments like methotrexate or similar medications. Participants in the study will receive either risankizumab or adalimumab, and their progress will be monitored over a period of time to see how their symptoms change.

The study will last for about 124 weeks, during which time participants will have regular check-ups to assess their response to the treatment. The main goal is to see if the children achieve a significant improvement in their arthritis symptoms by the 24th week of the study. Additional assessments will be made to measure changes in pain levels, skin symptoms, and overall disease activity. This information will help determine the effectiveness and safety of risankizumab for treating juvenile psoriatic arthritis in children.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be assessed to confirm a diagnosis of juvenile psoriatic arthritis. This includes having active disease in at least three joints.

    The patient must have previously shown an inadequate response or intolerance to certain medications such as methotrexate or other similar treatments.

  2. Step 2

    Initial treatment phase

    The patient will begin treatment with either risankizumab or adalimumab. Both medications are administered as a solution for injection under the skin.

    The specific dosage and frequency of administration will be determined by the study protocol and the patient's individual needs.

  3. Step 3

    Monitoring and assessment

    Throughout the study, the patient's response to the medication will be closely monitored. This includes regular assessments of joint activity and overall health.

    The primary goal is to achieve a significant improvement in symptoms by Week 24, as measured by specific criteria for juvenile arthritis.

  4. Step 4

    Evaluation of treatment effectiveness

    At Week 24, the patient's progress will be evaluated to determine the effectiveness of the treatment. This includes measuring changes in joint activity and other health indicators.

    Secondary outcomes will also be assessed, such as improvements in pain levels and skin symptoms if applicable.

  5. Step 5

    Continuation or adjustment of treatment

    Based on the results at Week 24, the treatment plan may be continued or adjusted to better meet the patient's needs.

    The study aims to provide ongoing support and monitoring to ensure the best possible outcomes for the patient.

Who can join the trial?

5 criteria

  • The patient must have been diagnosed with **Juvenile Psoriatic Arthritis (jPsA)**, which is a type of arthritis that affects children, for at least 6 months before the start of the study.
  • The patient must have **active disease** in 3 or more joints at the time of screening and at the beginning of the study. Active disease means the joints are swollen (not due to deformity) or have limited movement with pain or tenderness.
  • The patient must have tried treatment with at least one of the following medications and found them not effective or could not tolerate them: **Methotrexate (MTX)**, **sulfasalazine**, **leflunomide**, or **hydroxychloroquine**. These are medications used to treat arthritis.
  • The patient must be between the ages of 5 and less than 18 years old.
  • Both male and female patients can participate in the study.

Who cannot join the trial?

3 criteria

  • Patients who have not had an inadequate response to, or are not intolerant of, methotrexate (MTX) or other csDMARDs cannot participate. **Methotrexate (MTX)** is a medication used to treat certain types of arthritis, and **csDMARDs** are a group of drugs that slow down the disease process in arthritis.
  • Patients who are not within the age range of 5 to less than 18 years cannot participate.
  • Patients who do not have active **Juvenile Psoriatic Arthritis** cannot participate. **Juvenile Psoriatic Arthritis** is a type of arthritis that affects children and is associated with a skin condition called psoriasis.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Risankizumab

    is a medication being studied for its effectiveness, safety, and tolerability in treating children with active juvenile psoriatic arthritis. It is administered through an injection under the skin and is being compared to another treatment to see how well it works in reducing symptoms of the condition.

  • Adalimumab

    is used as a reference treatment in this study. It is a well-known medication for treating various inflammatory conditions, including juvenile psoriatic arthritis. It helps reduce inflammation and relieve symptoms by targeting specific proteins in the immune system.

  • Methotrexate

    is a medication that some participants in the study may have previously used. It is commonly prescribed for juvenile psoriatic arthritis to help control inflammation and slow down the progression of the disease. However, some children may not respond well to it or may experience side effects, which is why alternative treatments are being explored in this trial.

What is already known about the treatment

  • Risankizumab

    This medication is administered through subcutaneous injection and is currently being studied for its effectiveness and safety in treating juvenile psoriatic arthritis. It is in the clinical trial phase, where its efficacy and tolerability are being compared to adalimumab in children and adolescents. Risankizumab is primarily indicated for conditions involving inflammation, such as juvenile psoriatic arthritis. It works by targeting and inhibiting a specific protein in the immune system called interleukin-23 (IL-23), which plays a role in inflammatory processes. It is classified as a monoclonal antibody used in the treatment of autoimmune diseases.

  • Adalimumab

    This medication is also administered via subcutaneous injection and serves as a reference treatment in the clinical trial for juvenile psoriatic arthritis. It is a well-established medication in medical literature, widely used for various inflammatory conditions. Adalimumab is indicated for reducing inflammation and pain in conditions like juvenile psoriatic arthritis. It functions by blocking tumor necrosis factor-alpha (TNF-alpha), a substance in the body that causes inflammation. It is classified as a TNF inhibitor, commonly used in the management of autoimmune diseases.

Investigated diseases

Juvenile Psoriatic Arthritis – This is a type of arthritis that affects children and adolescents, typically characterized by joint inflammation and skin symptoms similar to psoriasis. It can cause swelling, stiffness, and pain in the joints, often accompanied by patches of red, scaly skin. The disease may progress with periods of increased symptoms, known as flares, and periods of remission where symptoms improve. Over time, it can lead to joint damage if not managed properly. The condition can vary greatly in severity and may affect different joints in the body.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2023-506026-36-00Protocol codeM23-732Estimated enrolment40 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).